CoLucid Pharmaceuticals starts out with an in-licensed migraine drug from Eli Lilly, one of a new class of molecules known as neurally acting anti-migraine agents. The phase II drug has demonstrated equal efficacy to triptans in the control of migraine symptoms without triptans' risk of cardiovascular side effects. CoLucid is also developing a wake-promotion drug using technology licensed from Sention.
2530 Meridian Parkway
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.
CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.
A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand
Bourla said the pharma industry may be able to negotiate productive solutions to Trump tariff and drug pricing concerns. He asserted anti-science views are not shared by all in the administration.
Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.
CEO Len Schleifer explained on the company’s Q1 earnings call that most of the complete response letters the company has received related to third-party suppliers, not efficacy or safety.
